MDM2 and leukemia: Using HLA-A2 transgenic mice and the allo-restricted strategy to circumvent tolerance to MDM2, we have previously demonstrated that CTL specific for an HLA-A2 presented peptide can kill a panel of human leukemia cell lines, while MDM2 expression levels in normal cells were too low to trigger CTL killing [26].